# Structure Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/structure-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.structuretx.com
- Total disclosed funding: $191M
- Latest round: Series B (Aug 1, 2022)
- Investors on record: 21

## About

Founded in 2016 and based in California, US, Structure Therapeutics Inc., formerly trading under the name ShouTi, Inc., operates as a biotechnology company that develops medicines for patients with chronic diseases, including cardiovascular, metabolic, and pulmonary conditions. The company's CEO Dr. Stevens has been involved in the discovery and development of several therapeutic molecules including Palnziq, which was developed at BioMarin Pharmaceutical and approved in 2018 to treat phenylketonuria. He also founded Receptos which developed Zeposia—a GPCR agonist targeting the S1PR1 receptor approved in 2020 for multiple sclerosis and 2021 for ulcerative colitis. In February 2023, Structure Therapeutics Inc. raised USD 161.1 million in an IPO at USD 15 per share on the Nasdaq under the ticker symbol "GPCR". The company focuses on G-protein coupled receptors (GPCRs). Its platform enables the conversion of biologics and peptide therapeutics into orally available small molecule drugs with enhanced pharmaceutical properties, including improved bioavailability and stability. Using artificial intelligence, machine learning, and other techniques, the company designs small molecules intended to address validated targets of biologic drugs.

## Funding rounds

- Series B, Aug 1, 2022, $33M — Piper Sandler, Deep Track Capital
- Series B, Jul 30, 2021, $100M — Hong Shan, Qiming Venture Partners, Eight Roads Ventures, F-Prime Capital, Lilly Asia Ventures, Sage Partners, Schrodinger, LLC, Casdin Capital, Cormorant Asset Management, Monashee Investment Management, TF Capital, Janus Henderson Investors, Surveyor Capital, Terra Magnum Capital Partners, Woodline Partners, Wuxi AppTec Group, TCG Crossover Management, Stork Capital Sàrl, Bvf Partners L.P.
- Series A, Mar 11, 2020, $26M — Qiming Venture Partners
- Series A, Apr 29, 2019, $32M — Qiming Venture Partners, F-Prime Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Hong Shan — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Sage Partners (https://capitalatlas.ai/funds/sage-partners) — Series B
- Schrodinger, LLC — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Monashee Investment Management — Series B
- TF Capital — Series B
- Janus Henderson Investors — Series B
- Surveyor Capital — Series B
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B
- Woodline Partners — Series B
- Wuxi AppTec Group — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- Stork Capital Sàrl — Series B
- Bvf Partners L.P. — Series B
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B